Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# SFB 1709: RESEARCHING CELLULAR PLASTICITY

## Sitemaps
[XML Sitemap](https://www.sfb1709.de/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Beyond the Seminar: CRC1709 launches a new networking format for Early Career Researchers](https://www.sfb1709.de/beyond-the-seminar-crc1709-launches-a-new-networking-format-for-early-career-researchers/): On July 27, 2026, CRC1709 was pleased to welcome Prof. Brian Huntly from the University of Cambridge for a day of scientific exchange focused on acute myeloid leukaemia, gene regulation, and academic career development.
- [CRC1709 welcomes Prof. Brian Huntly as invited speaker](https://www.sfb1709.de/crc1709-welcomes-prof-brian-huntly-as-invited-speaker/): As part of the CRC1709 Invited Speaker Series, we are pleased to welcome Prof. Brian Huntly from the University of Cambridge.
- [New Publication in Blood: Single-cell MRD reveals AML patients benefiting from CXCR4 inhibition](https://www.sfb1709.de/new-publication-single-cell-mrd-reveals-patients-benefiting-from-cxcr4-inhibition/): CRC 1709 postdoctoral researcher Enise Ceran is the first author of a new study published in Blood, demonstrating how single-cell measurable residual disease (scMRD) profiling can identify patients with acute myeloid leukemia (AML) who are most likely to benefit from targeted CXCR4 inhibition after remission. The project was conducted in the laboratory of CRC 1709 Principal Investigator Carsten Müller-Tidow and forms part of the B06 research project.
- [CRC1709 Postdoc Karin Prummel Presents New Insights into AML Bone Marrow Niche Remodeling](https://www.sfb1709.de/crc1709-postdoc-karin-prummel-presents-new-insights-into-aml-bone-marrow-niche-remodeling/): CRC1709 congratulates Karin Prummel, postdoctoral researcher B05 & B07, on a series of outstanding scientific achievements highlighting the impact of her work within CRC1709.
- [Upcoming Research in Progress Session on July 13, 2026](https://www.sfb1709.de/upcoming-research-in-progress-session-on-july-13-2026/): We are pleased to announce that the next Research in Progress meeting will take place on Monday, July 13, 2026, at 4:00 pm in the Main Lecture Hall (Hörsaal), University Hospital Heidelberg, INF 410.
- [CRC1709 Early Career Researcher Fengbiao Zhou Presents Novel AML Research at EHA 2026](https://www.sfb1709.de/crc1709-early-career-researcher-fengbiao-zhou-presents-novel-aml-research-at-eha-2026/): CRC1709 congratulates our Early Career Researcher Fengbiao Zhou on his successful presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden.
- [Upcoming Research in Progress Session on June 29, 2026](https://www.sfb1709.de/upcoming-research-in-progress-session-on-june-29-2026/): We are pleased to announce that the next Research in Progress meeting will take place on Monday, June 29, 2026, at 4:00 pm in the Main Lecture Hall (Hörsaal), University Hospital Heidelberg, INF 410.
- [Building Infrastructure Through Dialogue: CRC1709 Successfully Hosts Second INF In-Person Workshop](https://www.sfb1709.de/building-infrastructure-through-dialogue-crc1709-successfully-hosts-second-inf-in-person-workshop/): On June 15, 2026, the CRC1709 INF Project successfully hosted its second INF In-Person Workshop in Heidelberg, bringing together Data Management Officers (DMOs) and members of the INF team for an intensive three-hour exchange on research, computational needs, and future infrastructure development.
- [CRC1709 Researchers Contribute to Cell Stem Cell Publication on Therapy Resistance in Acute Myeloid Leukemia](https://www.sfb1709.de/crc1709-researchers-contribute-to-cell-stem-cell-publication-on-therapy-resistance-in-acute-myeloid-leukemia/): We are delighted to congratulate several CRC1709 researchers on their contribution to a new publication in Cell Stem Cell:
- [Upcoming Research in Progress Session on June 1, 2026](https://www.sfb1709.de/upcoming-research-in-progress-session-on-june-1-2026/): We are pleased to announce that the next Research in Progress meeting will take place on Monday, June 1, 2026, at 4:00 pm in the Main Lecture Hall (Hörsaal), University Hospital Heidelberg, INF 410.
- [Exploring AI and Plasticity in Biomedical Research: CRC1709 Summer School 2026](https://www.sfb1709.de/exploring-ai-and-plasticity-in-biomedical-research-crc1709-summer-school-2026/): The CRC1709 Summer School 2026 will take place in Heidelberg on September 1-2, 2026.
- [CRC1709 PI Alwin Krämer Receives Paul Martini Prize 2026](https://www.sfb1709.de/crc1709-pi-alwin-kramer-receives-paul-martini-prize-2026/): We are delighted to congratulate Professor Alwin Krämer, Principal Investigator in CRC 1709, on being awarded the prestigious Paul Martini Prize 2026.
- [CRC1709 Research Highlight: Targeting Mitochondrial Vulnerabilities in Drug-Resistant Leukemia](https://www.sfb1709.de/crc1709-research-highlight-targeting-mitochondrial-vulnerabilities-in-drug-resistant-leukemia/): Understanding and overcoming therapy resistance remains one of the central challenges in cancer research. A publication by Cornelius Pauli (A02 project) in Blood contributes important insights into this question.
- [CRC1709 Invited Speaker Series—May 4, 2026: Prof. Jérôme Tamburini on Iron Metabolism in AML](https://www.sfb1709.de/crc1709-invited-speaker-series-may-4-2026-prof-jerome-tamburini-on-iron-metabolism-in-aml/): As part of the CRC1709 Invited Speaker Series, we are pleased to welcome Prof. Jérôme Tamburini from the Geneva University Hospitals (HUG) and the University of Geneva.
- [Behind the Infrastructure: Marcel Kleinmann Drives Digital Innovation in CRC1709](https://www.sfb1709.de/behind-the-infrastructure-marcel-kleinmann-drives-digital-innovation-in-crc1709/): Modern biomedical research is driven not only by scientific discoveries in the laboratory, but also by secure digital infrastructure, intelligent data environments, and innovative computational tools. These systems enable researchers and clinicians to work more efficiently, collaboratively, and effectively. At CRC1709, one of the people helping to build this foundation is Marcel Kleinmann, Clinical AI & Data Systems Architect within the INF project.
- [Upcoming Research in Progress Session on April 20, 2026](https://www.sfb1709.de/upcoming-research-in-progress-session-on-april-20-2026/): We are pleased to announce that the next Research in Progress meeting, taking place on Monday, April 20, 2026, at 4:00 pm in the Main Lecture Hall (Hörsaal), University Hospital Heidelberg, INF 410.
- [CRC1709 Retreat 2026 Successfully Held in Bad Dürkheim](https://www.sfb1709.de/crc1709-retreat-2026-successfully-held-in-bad-durkheim/): The CRC1709 Retreat 2026 was successfully held on February 23-24, 2026, at the Kurpark-Hotel Bad Dürkheim, bringing together nearly 90 participants from Heidelberg, Mannheim, Munich, Frankfurt, Berlin, and Basel for two days of scientific exchange, collaboration, and strategic discussion. As the first retreat of CRC1709, the event focused on strengthening internal collaboration among principal investigators, postdoctoral researchers, PhD students, and associated members of the consortium.
- [INF Project Launches New In-Person Workshop Format for Data Management Officers](https://www.sfb1709.de/inf-project-launches-new-in-person-workshop-format-for-data-management-officers/): On March 27, 2026, the CRC1709 INF project introduced a new in-person workshop format for Data Management Officers, complementing the existing online meetings. The new format aims to foster closer interaction, facilitate exchange of experiences, and strengthen collaboration across projects.
- [Gerok Position Supports Early Career Clinician Scientist—Haizhang Chen](https://www.sfb1709.de/gerok-position-supports-early-career-clinician-scientist-haizhang-chen/): From January to March 2026, Haizhang Chen (Assistant Physician, Med V, University Hospital Heidelberg) was supported through a Gerok position within CRC1709. During this period, he conducted experimental work in the laboratory and contributed to the B01 project.
- [Early Career Researcher Board Elected at CRC1709 Retreat](https://www.sfb1709.de/early-career-researcher-board-elected-at-crc1709-retreat/): During the recent CRC1709 retreat, we were pleased to elect the new Early Career Researcher (ECR) Board, representing junior principal investigators, postdoctoral researchers, and PhD students across the CRC community.
- [Research in Progress Series | 2026](https://www.sfb1709.de/excepteur-sint-occaecat-cupidatat-non-proident/): The Research in Progress sessions form the living core of the CRC 1709 Lecture Series. They provide a dedicated space for our participating groups to share ongoing projects, emerging data, and evolving ideas within the framework of Cellular Plasticity in Myeloid Malignancies – From Mechanisms to Therapies.
- [Announcement: Invited Speakers  Series | 2026](https://www.sfb1709.de/diam-volutpat-commodo-sed-egestas-egestas-fringilla/): We are delighted to present the Invited Speaker program of the CRC 1709 Lecture Series 2026, featuring a stellar lineup of internationally recognized researchers alongside upcoming dates that promise exciting scientific contributions to the fields of myeloid biology, stem cell research, cancer epigenetics, and translational medicine.
- [Upcoming Lecture Series | 2026](https://www.sfb1709.de/condimentum-mattis-pellentesque-id-nibh-tortor/): We are pleased to announce the 2026 Lecture Series of CRC 1709, Cellular Plasticity in Myeloid Malignancies – From Mechanisms to Therapies. The series brings together leading international experts and members of our consortium to explore how cellular plasticity shapes myeloid diseases and how these insights can be translated into innovative therapeutic strategies.

## Pages
- [Imprints](https://www.sfb1709.de/imprints/): Heidelberg University Hospital (Universitätsklinikum Heidelberg)
- [Events](https://www.sfb1709.de/events/): Events
- [Publications](https://www.sfb1709.de/publications/)
- [Contact](https://www.sfb1709.de/contact/): Contact
- [News](https://www.sfb1709.de/news/)
- [About the CRC](https://www.sfb1709.de/about/): About the CRC 1709
- [Research](https://www.sfb1709.de/research/): Research Areas & Core Projects
- [Home](https://www.sfb1709.de/): The Collaborative Research Center CRC1709—Cellular Plasticity in Myeloid Malignancies investigates how cancer cells dynamically change their identity, behavior, and function. By understanding this plasticity, we aim to develop new therapeutic strategies that prevent resistance, relapse, and disease progression.
- [Privacy Policy (GDPR)](https://www.sfb1709.de/privacy-policy/): Last updated: 10 February 2026

## Content Blocks
- [News_on_Homepage](https://www.sfb1709.de/ct_content_block/news_on_homepage-2/)
- [News_on_Homepage](https://www.sfb1709.de/ct_content_block/news_on_homepage-3/)
- [News_on_Homepage](https://www.sfb1709.de/ct_content_block/news_on_homepage/)
- [Maintenance Mode Front Page](https://www.sfb1709.de/ct_content_block/maintenance-mode-front-page/): Our website is currently undergoing scheduled maintenance.Thank you for your understanding.
- [Lead Investigator](https://www.sfb1709.de/ct_content_block/lead-investigator/)
- [Member Single Details](https://www.sfb1709.de/ct_content_block/member-single-details/): Deputy Spokesperson, Lead Investigator
- [Publications Details](https://www.sfb1709.de/ct_content_block/research-project-details-2/): Read More
- [Hero Publications Archive](https://www.sfb1709.de/ct_content_block/hero-publications-archive/): Publications
- [Events Details](https://www.sfb1709.de/ct_content_block/events-details/): Adam Wilkinson
- [Hero Events Archive](https://www.sfb1709.de/ct_content_block/hero-events-archive/): Events-Archive
- [Research Project Details](https://www.sfb1709.de/ct_content_block/research-project-details/): Cell-Intrinsic Factors (Area A)
- [Hero Member, Team](https://www.sfb1709.de/ct_content_block/hero-member-team/): Team & Partner
- [Funders & Partners](https://www.sfb1709.de/ct_content_block/funders/)

## Members
- [Adelheid Cerwenka, Prof. Dr. rer. nat.](https://www.sfb1709.de/members/prof-dr-adelheid-cerwenka/)
- [Alexander Wahl](https://www.sfb1709.de/members/alexander-wahl/)
- [Alwin Krämer, Prof. Dr. med.](https://www.sfb1709.de/members/prof-dr-alwin-kramer/)
- [Andrea Schmidts, Dr. med.](https://www.sfb1709.de/members/dr-andrea-schmidts/)
- [Andreas Reiter, Prof. Dr. med.](https://www.sfb1709.de/members/prof-dr-andreas-reiter/)
- [Andreas Trumpp, Prof. Dr. rer. nat.](https://www.sfb1709.de/members/prof-dr-andreas-trumpp/)
- [Annette Becker M.A.](https://www.sfb1709.de/members/annette-becker/)
- [Anuraag Ghosh](https://www.sfb1709.de/members/anuraag-ghosh/)
- [Archisman Maitra](https://www.sfb1709.de/members/archisman-maitra/)
- [Ashok Kumar Jayavelu, Ph.D.](https://www.sfb1709.de/members/dr-ashok-kumar-jayavelu/)
- [Axel Roers, Prof. Dr. med.](https://www.sfb1709.de/members/prof-dr-axel-roers/)
- [Aynur Yu Huang M.A., M.A.](https://www.sfb1709.de/members/aynur-yu-huang/)
- [Bahar Orhan](https://www.sfb1709.de/members/bahar-orhan/)
- [Binje Vick, Dr. rer. nat.](https://www.sfb1709.de/members/dr-binje-vick/)
- [Caroline Pabst, PD Dr. med.](https://www.sfb1709.de/members/dr-caroline-pabst/)
- [Carsten Müller-Tidow, Prof. Dr. med.](https://www.sfb1709.de/members/professor-mueller-tidow/)
- [Charles Dussiau, Ph.D.](https://www.sfb1709.de/members/dr-charles-dussiau/)
- [Christoph Plass, Prof. Dr. rer. nat.](https://www.sfb1709.de/members/prof-dr-christoph-plass/)
- [Cornelius Pauli, Dr. med.](https://www.sfb1709.de/members/dr-cornelius-pauli/)
- [Daniel Nowak, Prof. Dr.](https://www.sfb1709.de/members/prof-dr-daniel-nowak/)
- [Dominik Humer](https://www.sfb1709.de/members/dr-dominik-humer/)
- [Eleni Besiridou](https://www.sfb1709.de/members/eleni-besiridou/)
- [Emilija Marinkovic, Ph.D.](https://www.sfb1709.de/members/dr-emilija-marinkovic/)
- [Enise Ceran, Dr. med.](https://www.sfb1709.de/members/enise-ceran-dr-med/)
- [Franziska Blaeschke, Dr. rer.nat., Dr. med.](https://www.sfb1709.de/members/dr-dr-franziska-blaeschke/)
- [Hannah Uckelmann, Ph.D.](https://www.sfb1709.de/members/dr-hannah-uckelmann/)
- [Irmela Jeremias, Prof. Dr. med.](https://www.sfb1709.de/members/prof-dr-irmela-jeremias/)
- [Jakob Nikolas Kather, Prof. Dr. med., M.Sc.](https://www.sfb1709.de/members/prof-dr-jakob-nikolas-kather/)
- [Jeroen Krijgsveld, Prof. Dr.](https://www.sfb1709.de/members/prof-dr-jeroen-krijgsveld/)
- [Jiefu Zhu](https://www.sfb1709.de/members/dr-jiefu-zhu/)
- [Jill Maurah Leciejewski](https://www.sfb1709.de/members/jill-maurah-leciejewski/)
- [Judith Zaugg, Prof. Dr. rer. nat.](https://www.sfb1709.de/members/dr-judith-zaugg/)
- [Julia Herzberg](https://www.sfb1709.de/members/julia-herzberg/)
- [Junyan Lu, Ph.D.](https://www.sfb1709.de/members/dr-junyan-lu/)
- [Kaushani Banerjee](https://www.sfb1709.de/members/kaushani-banerjee/)
- [Keyi Ao](https://www.sfb1709.de/members/keyi-ao/)
- [Konstantinos Kokkaliaris, Ph.D.](https://www.sfb1709.de/members/dr-konstantinos-kokkaliaris/)
- [Lilian Frank](https://www.sfb1709.de/members/lilian-frank/)
- [Lisa Sippl](https://www.sfb1709.de/members/lisa-sippl/): Medical Faculty Mannheim, University of Heidelberg
- [Luisa Kinas](https://www.sfb1709.de/members/luisa-kinas/)
- [Lukas Schmitt](https://www.sfb1709.de/members/lukas-schmitt/)
- [Mahmud Shehab](https://www.sfb1709.de/members/mahmud-shehab/)
- [Maike Janssen, Dr. med.](https://www.sfb1709.de/members/dr-maike-janssen/)
- [Marcel Kleinmann, M.Sc.](https://www.sfb1709.de/members/marcel-kleinmann/)
- [Maria-Luisa Schubert, PD Dr. med.](https://www.sfb1709.de/members/dr-maria-luisa-schubert/)
- [Marieke Essers, Ph.D.](https://www.sfb1709.de/members/prof-dr-marieke-essers/)
- [Martin Dugas, Prof. Dr. med. Dipl.-Inform.](https://www.sfb1709.de/members/martin-schmidt/)
- [Maximilian Felix Blank, Dr. med.](https://www.sfb1709.de/members/dr-maximilian-felix-blank/)
- [Michael Milsom, Ph.D.](https://www.sfb1709.de/members/dr-michael-milsom/)
- [Michaela Frye, Prof. Dr. rer. nat.](https://www.sfb1709.de/members/prof-dr-michaela-frye/)

## Research
- [INF: Data Management, Information Infrastructure, and Application](https://www.sfb1709.de/research/inf/): The CRC1709 aims to integrate multi-dimensional data from compatible shared disease models regarding myeloid plasticity. For efficient and sustainable data management, a central data integration hub is established for the CRC. On this hub, all data relevant for the project are collected and integrated to allow for analysis and modelling across all data sources.
- [Z03: Proteomic and single-cell transcriptomic landscapes of cellular plasticity in myeloid malignancies](https://www.sfb1709.de/research/z03/): Transcriptomic, epigenomic and proteomic profiling are key technologies across the CRC to investigate and understand cell plasticity. Project Z03 will provide a technological platform for consistent and state-of-the-art proteome, single-cell transcriptome and chromatin accessibility analysis of cellular specimens collected from cell line systems, animal models, and patients under diverse types of treatment. Integration of multi-omics data from the CRC projects will provide an overarching view of common and shared regulatory programs that underlie cell plasticity allowing generation of a plasticity landscape for myeloid malignancies.
- [Z02: Clinically annotated primary tumor cells and mouse clinics for patient-derived xenograft (PDX) models](https://www.sfb1709.de/research/z02/): Within project Z02 all PIs of the CRC will be provided with (1) shared primary myeloid malignancy samples from the Heidelberg Cell and Liquid Biobank and (2) PDX mouse models for preclinical in vivo treatment assays. We are going to set up a dedicated Mouse Leukemia Clinic for analysis and treatment of PDX models. This mouse clinic will foster collaboration, accelerate research due to standardized procedures and will allow comparisons of diseases and treatment across individual projects. At the same time, the professional team will use all possible 3R criteria to reduce, refine and replace mouse experiments.
- [B11: Deciphering and therapeutically exploiting immunerelated cellular plasticity during allogeneic stem celltransplantation in myeloid malignancies](https://www.sfb1709.de/research/b11/): Project B11 aims to systematically study the role of donor-host interactions in mediating therapy outcome in MNs. In particular, by using primary samples from initial diagnosis, remission, pre-alloSCT and post-alloSCT and single cell multiomics B11 will focus on systematically dissecting the role of cellular plasticity that is observed in leukemic cells and the immune system as a direct consequence of cellular interactions between donor and host cells. B11 will identify molecular, cellular and immunological candidate pathways and mechanisms that mediate effective GvL or cause GvHD, and will assess whether blockade or boost of specific immune pathways can be used to improve the balance between positive GvL and adverse effects.
- [B10: Cellular plasticity driven by innate immune activation in DDX41-mediated myeloid malignancies](https://www.sfb1709.de/research/b10/): Using innovative techniques, including dynamic differentiation and fate tracking, 3D co-culture models, and clone tracing, project B10 will analyze the role of DDX41 in activation of cancer cell innate immune responses and how DDX41-mediated cGAS-STING signaling contributes to hematopoietic stem and progenitor cell plasticity and leukemogenesis. This project highlights how cell intrinsic properties (e.g. germline DDX41 mutations) affect innate immune response that may drive leukemogenesis via increased inflammation.
- [B09: Inflammation-driven plasticity in disease progression in Advanced Systemic Mastocytosis](https://www.sfb1709.de/research/b09/): By using AdvSM patient samples at different stages of the disease (pre-treatment, remission, primary resistance, and relapse/ secondary resistance) project B09 will characterize the inflammatory cytokine landscape and immune cell composition and dynamically map the inflammatory microenvironment. Using established mouse models of AdvSM disease progression in the absence or presence of induced inflammation using different pro-inflammatory cytokines will be analyzed and compared to patient´s data. Multi-omic analysis will identify changes induced by differences in pro-inflammatory cytokine levels that impact on disease progression.
- [B08: Spatial and epigenetic plasticity during leukemia development](https://www.sfb1709.de/research/b08/): Project B08 will unravel the spatial and epigenetic plasticity during leukemia development and targeted therapeutic intervention by using a pre-leukemic Npm1c knock-in mouse model, single cell multiomics approaches and spatial profiling of the bone marrow microenvironment. B08 will characterize the pre-leukemic niche of L-HSC clones resistant to epigenetic therapy, and the underlying mechanisms that support resistance to targeted epigenetic therapies.
- [B07: Single cell multi-omics to unravel niche plasticity in AML therapy resistance](https://www.sfb1709.de/research/b07/): Project B07 will apply single-cell and imaging technologies to characterize BM niche plasticity in AML during the course of the disease and treatment. Identified candidate genes will be functionally investigated by treating AML blasts with niche-targeting drugs acting against niche-induced LSC plasticity. These niche remodeling drugs will be subsequently combined with LSC- targeting drugs and their synergism will be assessed in vivo.
- [B06: Leukemia cell plasticity and NK cell activity as determinants of relapse in AML](https://www.sfb1709.de/research/b06/): Project B06 aims to identify cellular states of resistant AML blasts in first complete remission. Extended CITE-Seq analysis based on own surface proteomics data from primary AML will be used to characterize AML associated patterns of surface protein expression in the MRD positive setting. In the same CITE-Seq experiments, the microenvironment of MRD+ bone marrow with a special focus on NK cells will be characterized. Proprietary scFv phage libraries will be used to develop novel CAR constructs and CAR NK cells targeting AML associated patterns. These are then used to develop combinatorial off- the- shelf CAR NK cell products for effective targeting.
- [B05: Characterizing lineage plasticity of KMT2A/AFF1-rearranged acute leukemia under therapeutic pressure from CAR T cells](https://www.sfb1709.de/research/b05/): Project B05 will characterize lineage plasticity of KMT2A-rearranged acute leukemia under therapeutic pressure from CAR-T cells. Mechanisms mediating the lymphoid to myeloid lineage switch upon CD19 CAR T cell therapy will be analyzed using primary samples and combined single-cell transcriptomics and clonal tracking. Lineage-switch mechanisms will be further studied in KMT2A/AFF1 leukemia PDX-mouse models, and combination treatments for KMT2A/AFF1 leukemias using hypomethylating agents and CAR-Ts will be developed and optimized.
- [B04: Dissecting mechanisms of immunotherapy-induced plasticity in AML through multi-omics and genome-wide CRISPR screens](https://www.sfb1709.de/research/b04/): Project B04 will characterize the impact of the inflammatory AML environment and identify mechanisms of AML plasticity in response to therapeutic pressure mediated by CAR T cells targeting CD33 and CD70, and ADCs such as gemtuzumab ozogamicin. B04 will utilize single-cell multiomics analyses and genome-wide CRISPR knockout and overexpression screens to uncover the mechanisms that hinder the effectiveness of immunotherapy in AML, enabling the development of novel and innovate treatment strategies that will overcome these limitations.
- [B03: Multi-modal proteomics to understand and overcome nicherelatedadaptive drug-resistance mechanisms in FLT3-mutated AML](https://www.sfb1709.de/research/b03/): Project B03 will apply multi-modal proteomics to understand and overcome adaptive drug-resistance mechanisms in FLT3-mutated AML. Using primary AML cells, PDX and cell line models, and CRISPR-based screens, drug screens, RNAseq and proteomic approaches B03 will decipher how plasticity of FLT3-mutated AML cells leads to TKI-resistance, and will identify novel vulnerabilities in TKI-resistant cells.
- [B02: Investigation into the plastic state of dormancy in JAK2-V617F driven myeloproliferative neoplasms (MPNs) and secondary acute myeloid leukemias (sAMLs)](https://www.sfb1709.de/research/b02/): Project B02 will analyze the JAK2-inhibitor-mediated modulation of the plastic state of dormancy during the transition of JAK2-V617F-driven Myeloproliferative Neoplasms (MPNs) into secondary myelofibrosis (sMF) and secondary acute myeloid leukemia (sAML). Using mouse models of Polycythemia Vera (PV), sMF and sAML, as well as patient-derived material and xenografts, B02 aims to explore whether dormancy within the mutant HSC compartment plays a biologically-relevant role in JAK2VF disease propagation, as well as in relapse after JAK2 inhibitor treatment. Perturbation of candidate genes regulating the state of dormancy will reveal novel therapeutic targets of dormant, JAK2-inhibitor resistant malignant cells.
- [A07: Myeloid antigen plasticity as critical determinant of AML immune surveillance](https://www.sfb1709.de/research/a07/): Project A07 will explore regulatory networks shaping the immunopeptidome produced by AML blasts and analyzes the respective TCR responses. This project relies on the recently completed TEAM trial which examined the combination of Bortezomib as proteasome inhibitor with cytarabin and the anti-CD33 antibody Gemtuzumab-Ozogamicin. Proteasome inhibition might alter the AML intrinsic immunopeptidome and thus increase potential TCR targets.
- [A06: Plastic growth behavior of patients’ AML in vivo: Releasing dormant cells from their protective niche](https://www.sfb1709.de/research/a06/): Using primary patient AML samples, PDX mouse models, single-cell/bulk omics profiling and integrative data analysis A06 will identify the underlying intra- and extra-cellular regulators and regulatory networks responsible for the switch from dormancy to the actively proliferating state of LSCs. Given the reversibility of the plastic phenotype, novel therapeutic approaches to release resistant LSCs from their protective bone marrow environment in order to convert them into treatment-responsive cells shall be investigated by reverse genetics in PDX models in vivo.
- [A05: Deciphering plasticity of relapse-driving, chemo-resistant LSC states in DNMT3Amut NPM1mut AML](https://www.sfb1709.de/research/a05/): In project A05 single cell multi-omics will be applied to analyze triplet primary AML samples (diagnosis, remission, relapse) to identify reversible plastic LSC states and identify non-genetic molecular drivers of dormancy and thus resistance and relapse. Furthermore, A05 will elaborate metabolic LSC states along the AML therapy course using advanced cellular barcoding technologies to trace plasticity of distinct LSC states.
- [Z01: Central administration](https://www.sfb1709.de/research/z01/): Efficient coordination and management of the CRC activities is instrumental for the success of the consortium. The CRC office of the Spokesperson will be in charge of the logistics, scientific coordination and management. We developed the projects to be highly collaborative and to benefit to the maximum extent from the synergism with other projects and the supporting Z-projects as well as the INF project. The CRC office will coordinate and support these activities.
- [B01: Predicting response to venetoclax/azacitidine in AML by determining cytologic variability in AML blasts with generative AI image analysis combined with single-celltranscriptomics](https://www.sfb1709.de/research/b01/): Project B01 will analyze variability of AML blasts as determinants of response to venetoclax and azacytidine treatment. Advanced multiomics scRNA-Seq and generative AI- based image analysis will be applied to paired primary samples (diagnosis/relapse) to integrate cellular morphology with molecular analyses in order to predict treatment outcomes and to identify novel VEN/AZA response biomarkers.
- [A04: Loss of Y chromosome in acute myeloid leukemia drives tumorcell plasticity and drug resistance](https://www.sfb1709.de/research/a04/): Project A04 proposes that loss of KDM5D, a chromosome Y-specific histone H3 lysine-4 demethylase, associates with deficiencies in DNA repair and increases epigenetic and functional plasticity of human AML cells with mosaic loss of Y chromosome (mLOY). Using sc-multi omics approaches on engineered LOY iPSC/HSPC cells and primary patient samples as well as PDX mouse models A04 will analyze whether mLOY creates haploinsufficiency in epigenetic enzymes encoded on the Y chromosome, resulting in epigenomic heterogeneity of H3K4me3 and determine the impact of KDM5D/UTY/KDM6C loss on the functional plasticity of AML stem cells.
- [A03: Targeting metabolic plasticity to overcome chemotherapyresistance in acute myeloid leukemia](https://www.sfb1709.de/research/a03/): Project A03 will identify key metabolic features (e.g., OXPHOS, FAO, glycolysis, ROS, etc.) of primary AML cells that survived chemotherapy using metabolic spectral flow cytometry. Bone marrow organoids will be established to analyze metabolic adaptation of AML and niche cells under cytotoxic stress caused by clinically approved compounds. Single cell multi-omics, able to simultaneously determine metabolic properties, transcriptome and surface proteome will be applied in order to identify targetable vulnerabilities upon metabolic adaptation.
- [A02: Mitochondrial RNA modification-driven metabolic plasticity in leukemic stem cells and drug resistance](https://www.sfb1709.de/research/a02/): Project A02 will map and quantify m1G levels in mitochondrial- and nuclear-encoded tRNAs in healthy hematopoietic stem and progenitor cells and matched leukemia samples (diagnosis and relapse). Subsequently, the underlying molecular mechanisms of how mitochondrial and cytosolic mRNA translation rates are coordinated in normal and malignant hematopoietic cells will be identified. Inhibition of oncogenic pathways inducing mitochondrial RNA modifications will test whether metabolic plasticity can be blocked and leukemic cells can be re-sensitized to anti-leukemic drug treatment.
- [A01: Functions of the dynamic ribosomal epitranscriptome in shaping myeloid plasticity](https://www.sfb1709.de/research/a01/): Using nanopore sequencing of single native RNA molecules from primary samples project A01 will comprehensively identify AML- associated epitranscriptomic changes in rRNA and its functional consequences for cellular plasticity. Regulators that induce specific rRNA modifications patterns, such as snoRNAs, will be characterized via focused CRISPR screens to identify therapeutic vulnerabilities.

## Events
- [Invited Speaker Series: Jan Henning Klusmann (University Hospital Frankfurt)](https://www.sfb1709.de/event/invited-speaker-series-jan-henning-klusmann-university-hospital-frankfurt/)
- [Invited Speaker Series: Rebekka Schneider (University Hospital Aachen)](https://www.sfb1709.de/event/invited-speaker-series-rebekka-schneider-university-hospital-aachen/)
- [Invited Speaker Series: Daniel Lipka (NCT)](https://www.sfb1709.de/event/invited-speaker-series-daniel-lipka-nct/)
- [Research in Progress Series: Lilian Frank (Pauli Group) & Luisa Kinas (Krämer Group)](https://www.sfb1709.de/event/research-in-progress-series-lilian-frank-pauli-group-luisa-kinas-kramer-group/): Chair: Eleni Besiridou (Raffel Group)
- [Research in Progress Series: Jiefu Zhu (Kather Group) & Alexander Wahl (Blank Group)](https://www.sfb1709.de/event/research-in-progress-series-jiefu-zhu-kather-group-alexander-wahl-blank-group/): Chair: Lena Schlautmann (Pabst Group)
- [Research in Progress Series: Dominic Depke (Sauer Group) & Maria-Luisa Schubert (Schubert Group)](https://www.sfb1709.de/event/research-in-progress-series-dominic-depke-sauer-group-maria-luisa-schubert-schubert-group/): Chair: David Schmidl (Frye Group)
- [Research in Progress Series: Jonas Becker (Plass Group) & Julian Zoller (Friedrich Group)](https://www.sfb1709.de/event/research-in-progress-series-jonas-becker-plass-group-julian-zoller-friedrich-group/): Chair: Juliane Schmidt (Feurstein Group)
- [Research in Progress Series: Eleni Besiridou (Raffel Group) & David Schmidl (Frye Group)](https://www.sfb1709.de/event/crc1709-research-in-progress-eleni-besiridou-raffel-group-david-schmidl-frye-group/): Chair: Mahmud Shehab (Reiter Group)
- [CRC1709 INF in-Person Workshop](https://www.sfb1709.de/event/crc1709-inf-in-person-workshop-2/): This workshop is open to CRC1709 Data Management Officers and by invitation only.
- [CRC1709 INF Monthly Meeting—April](https://www.sfb1709.de/event/crc1709-inf-monthly-meeting/): This online event is only open to CRC1709 Data Management Officers.
- [CRC1709 INF in-Person Workshop](https://www.sfb1709.de/event/crc1709-inf-in-person-workshop/): This event is only open to CRC1709 Data Management Officers.
- [Research in Progress Series: Maximilian Nuber (Lu Group) & Julia Herzberg (Janssen Group)](https://www.sfb1709.de/event/research-in-progress-maximilian-number-lu-group-n-n/): Chair: Jonas Becker (Plass Group)
- [Research in Progress Series: Marcel Müller (Uckelmann Group) & Ines Simo-Vesperinas (Haas Group)](https://www.sfb1709.de/event/research-in-progress-ines-simo-vesperinas-haas-group-n-n/): Chair: Johanna Franz (Blaeschke Group)
- [Invited Speaker Series: Brian Huntly (University of Cambridge)](https://www.sfb1709.de/event/invited-speaker-brian-huntly-university-of-cambridge/)
- [Invited Speaker Series: Jérôme Tamburini Bonnefoy (Geneva University Hospitals HUG and University of Geneva)](https://www.sfb1709.de/event/invited-speaker-jerome-tamburini-bonnefoy-geneva-university-hospitals-hug-and-university-of-geneva/): We are excited to host Prof. Jérôme Tamburini Bonnefoy on May 4. With leadership roles at Geneva University Hospitals and the University of Geneva, Prof. Tamburini Bonnefoy is known for his contributions to clinical research in hematology and translational approaches for hematological malignancies. His insights from integrating basic scientific discovery with patient-centric studies will be a highlight of this year’s series.
- [Research in Progress Series: Abdul Itani (Essers Group) & Tomas Hofman (Cerwenka Group)](https://www.sfb1709.de/event/research-in-progress-2/): Chair: Michael Kienhöfer (Pauli Group)
- [CRC1709 Retreat—2026](https://www.sfb1709.de/event/research-in-progress/): Press release: CRC1709 Retreat 2026 Successfully Held in Bad Dürkheim - SFB 1709
- [Invited Speaker Series: Efrat Shema (Weizmann Institute of Science)](https://www.sfb1709.de/event/haematopoietic-stem-cell-expansion-technology-to-biology-3/): On February 9, we welcome Dr. Efrat Shema, an Assistant Professor at the Weizmann Institute of Science. Dr. Shema’s lab develops and applies cutting-edge single-molecule and single-cell technologies to visualize the epigenome and decipher mechanisms of genome regulation in cancer. Her work aims to uncover fundamental epigenetic deregulation and identify vulnerabilities that could inform novel therapeutic strategies.
- [Research in Progress Series: Patrick Stelmach (Trumpp Group) & Sercan Öz (Jeremias Group)](https://www.sfb1709.de/event/haematopoietic-stem-cell-expansion-technology-to-biology-5/): Chair: Elif Ceren Saf (Milsom Group)
- [Invited Speaker Series: Thomas Höfer (DKFZ)](https://www.sfb1709.de/event/haematopoietic-stem-cell-expansion-technology-to-biology/): Speaker Biography
- [Invited Speaker Series: Adam Wilkinson (Cambridge Stem Cell Institute)](https://www.sfb1709.de/event/haematopoietic-stem-cell-expansion-technology-to-biology-2/): 


## Publications
- [A kinetics-based model of haematopoiesisreveals extrinsic regulation of skewed lineageoutput from stem cells](https://www.sfb1709.de/publications/a-kinetics-based-model-of-haematopoiesisreveals-extrinsic-regulation-of-skewed-lineageoutput-from-stem-cells/)
- [Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells](https://www.sfb1709.de/publications/disrupting-trna-modifications-to-target-mitochondrial-vulnerabilities-in-drug-resistant-leukemia-cells/): Cornelius Pauli, Michael Kienhöfer, Maximilian Felix Blank, Oguzhan Begik, Christian Rohde, Sarah Miriam Naomi Zimmermann, Laura Werner, Daniel Heid, Fu Xu, Katharina Weidenauer, Sylvain Delaunay, Nadja Krall, Katrin Trunk, Duoduo Zhao, Fengbiao Zhou, Laia Llovera, Alexane Ollivier, Anke Heit-Mondrzyk, Uwe Platzbecker, Claudia Baldus, Hubert Serve, Martin Bornhäuser, Cathrine Broberg Vågbø, Salvador Aznar Benitah, Jeroen Krijgsveld, Eva Maria Novoa, Carsten Müller-Tidow, Michaela Frye